What should success look like in obesity treatment when the number on the scale is no longer enough? That was the question for the first panel on the second day of BioStock Life Science Summit 2026, where industry leaders discussed what is moving the field beyond the first generation of GLP-1 therapies.
Moderated by Claus Henrik Johansen, CEO of Global Health Invest, the panel brought together Eva Dahlén, Global Evaluation Director at Novo Nordisk, Fredrik Meurling, CEO of Yazen, and Mads Tang-Christensen, CSO of Antag Therapeutics. The discussion covered individualised patient care and the shift in focus from weight loss alone to preserving lean mass and muscle function. Following the rollout of oral treatments in the US, the panellists also discussed patient uptake of oral versus injectable therapies, as well as treatment adherence more broadly.
The session also set out to explore how emerging mechanisms, from amylin analogues and multi-incretin pathways to novel receptor targets, could address current treatment gaps, and what data early-stage companies need to spark interest from big pharma.
See the full panel discussion “The Obesity Race 2.0: Beyond the Scale” below.
